{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:22:19Z","timestamp":1790256139162,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004361","name":"Krebsliga Schweiz","doi-asserted-by":"publisher","award":["KFS-4230-08-2017"],"award-info":[{"award-number":["KFS-4230-08-2017"]}],"id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Proteasome inhibitors, such as bortezomib, are first-line therapy against multiple myeloma (MM). Unfortunately, patients frequently become refractory to this treatment. The transcription factor NRF1 has been proposed to initiate an adaptation program that regulates proteasome levels. In the context of proteasome inhibition, the cytosolic protease DDI2 cleaves NRF1 to release an active fragment that translocates to the nucleus to promote the transcription of new proteasome subunits. However, the contribution of the DDI2-NRF1 pathway to bortezomib resistance is poorly understood. Here we show that upon prolonged bortezomib treatment, MM cells become resistant to proteasome inhibition by increasing the expression of DDI2 and consequently activation of NRF1. Furthermore, we found that many MM cells became more sensitive to proteasome impairment in the context of DDI2 deficiency. Mechanistically, we demonstrate that both the protease and the HDD domains of DDI2 are required to activate NRF1. Finally, we show that partial inhibition of the DDI2-protease domain with the antiviral drug nelfinavir increased bortezomib susceptibility in treated MM cells. Altogether, these findings define the DDI2-NRF1 pathway as an essential program contributing to proteasome inhibition responses and identifying DDI2 domains that could be targets of interest in bortezomib-treated MM patients.<\/jats:p>","DOI":"10.1038\/s41419-022-04925-3","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T18:07:01Z","timestamp":1652983621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-3516","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Op","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio T.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Chavarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"De Gassart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Zaffalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6969-822X","authenticated-orcid":false,"given":"Fabio","family":"Martinon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"4925_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"4925_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43:676\u201381.","journal-title":"Semin Oncol"},{"key":"4925_CR3","unstructured":"Honjo T, Alt FW, Neuberger MS. Molecular biology of B cells. Amsterdam: Elsevier; 2004. xiv, pp. 589."},{"key":"4925_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41580-019-0101-y","volume":"20","author":"MS Hipp","year":"2019","unstructured":"Hipp MS, Kasturi P, Hartl FU. The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol. 2019;20:421\u201335.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4925_CR5","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","volume":"169","author":"GA Collins","year":"2017","unstructured":"Collins GA, Goldberg AL. The logic of the 26S proteasome. Cell. 2017;169:792\u2013806.","journal-title":"Cell."},{"key":"4925_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","volume":"5","author":"J Adams","year":"2004","unstructured":"Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004;5:417\u201321.","journal-title":"Cancer Cell"},{"key":"4925_CR7","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071\u20136.","journal-title":"Cancer Res"},{"key":"4925_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/jjco\/hyy108","volume":"48","author":"K Okazuka","year":"2018","unstructured":"Okazuka K, Ishida T. Proteasome inhibitors for multiple myeloma. Jpn J Clin Oncol. 2018;48:785\u201393.","journal-title":"Jpn J Clin Oncol"},{"key":"4925_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","volume":"26","author":"A Besse","year":"2019","unstructured":"Besse A, Besse L, Kraus M, Mendez-Lopez M, Bader J, Xin BT, et al. Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors. Cell Chem Biol. 2019;26:340\u201351. e3","journal-title":"Cell Chem Biol"},{"key":"4925_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","volume":"18","author":"D Niewerth","year":"2015","unstructured":"Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat. 2015;18:18\u201335.","journal-title":"Drug Resist Updat"},{"key":"4925_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-3-030-38266-7_6","volume":"1233","author":"M Gonzalez-Santamarta","year":"2020","unstructured":"Gonzalez-Santamarta M, Quinet G, Reyes-Garau D, Sola B, Roue G, Rodriguez MS. Resistance to the proteasome inhibitors: lessons from multiple myeloma and mantle cell lymphoma. Adv Exp Med Biol. 2020;1233:153\u201374.","journal-title":"Adv Exp Med Biol"},{"key":"4925_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molcel.2010.02.029","volume":"38","author":"SK Radhakrishnan","year":"2010","unstructured":"Radhakrishnan SK, Lee CS, Young P, Beskow A, Chan JY, Deshaies RJ. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell. 2010;38:17\u201328.","journal-title":"Mol Cell"},{"key":"4925_CR13","doi-asserted-by":"publisher","first-page":"e1002119","DOI":"10.1371\/journal.pgen.1002119","volume":"7","author":"X Li","year":"2011","unstructured":"Li X, Matilainen O, Jin C, Glover-Cutter KM, Holmberg CI, Blackwell TK. Specific SKN-1\/Nrf stress responses to perturbations in translation elongation and proteasome activity. PLoS Genet. 2011;7:e1002119.","journal-title":"PLoS Genet"},{"key":"4925_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.molcel.2010.09.012","volume":"40","author":"J Steffen","year":"2010","unstructured":"Steffen J, Seeger M, Koch A, Kruger E. Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol Cell. 2010;40:147\u201358.","journal-title":"Mol Cell"},{"key":"4925_CR15","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.cub.2014.06.004","volume":"24","author":"Z Sha","year":"2014","unstructured":"Sha Z, Goldberg AL. Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97. Curr Biol. 2014;24:1573\u201383.","journal-title":"Curr Biol"},{"key":"4925_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.006","volume":"107","author":"J Hagenbuchner","year":"2016","unstructured":"Hagenbuchner J, Ausserlechner MJ. Targeting transcription factors by small compounds\u2014current strategies and future implications. Biochem Pharmacol. 2016;107:1\u201313.","journal-title":"Biochem Pharmacol"},{"key":"4925_CR17","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1021\/acscentsci.7b00224","volume":"3","author":"FM Tomlin","year":"2017","unstructured":"Tomlin FM, Gerling-Driessen UIM, Liu YC, Flynn RA, Vangala JR, Lentz CS, et al. Inhibition of NGLY1 inactivates the transcription factor Nrf1 and potentiates proteasome inhibitor cytotoxicity. ACS Cent Sci. 2017;3:1143\u201355.","journal-title":"ACS Cent Sci"},{"key":"4925_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.cell.2019.03.035","volume":"177","author":"NJ Lehrbach","year":"2019","unstructured":"Lehrbach NJ, Breen PC, Ruvkun G. Protein sequence editing of SKN-1A\/Nrf1 by peptide:N-glycanase controls proteasome gene expression. Cell. 2019;177:737\u201350.","journal-title":"Cell."},{"key":"4925_CR19","doi-asserted-by":"publisher","first-page":"e18357.","DOI":"10.7554\/eLife.18357","volume":"5","author":"S Koizumi","year":"2016","unstructured":"Koizumi S, Irie T, Hirayama S, Sakurai Y, Yashiroda H, Naguro I, et al. The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction. elife. 2016;5:e18357.","journal-title":"elife"},{"key":"4925_CR20","doi-asserted-by":"publisher","first-page":"327.","DOI":"10.3390\/ijms21010327","volume":"21","author":"A Northrop","year":"2020","unstructured":"Northrop A, Vangala JR, Feygin A, Radhakrishnan SK. Disabling the protease DDI2 attenuates the transcriptional activity of NRF1 and potentiates proteasome inhibitor cytotoxicity. Int J Mol Sci. 2020;21:327.","journal-title":"Int J Mol Sci"},{"key":"4925_CR21","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1073\/pnas.1514076113","volume":"113","author":"A De Gassart","year":"2016","unstructured":"De Gassart A, Bujisic B, Zaffalon L, Decosterd LA, Di Micco A, Frera G, et al. An inhibitor of HIV-1 protease modulates constitutive eIF2alpha dephosphorylation to trigger a specific integrated stress response. Proc Natl Acad Sci USA. 2016;113:E117\u201326.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4925_CR22","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1073\/pnas.1019736108","volume":"108","author":"KL Meerbrey","year":"2011","unstructured":"Meerbrey KL, Hu G, Kessler JD, Roarty K, Li MZ, Fang JE, et al. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci USA. 2011;108:3665\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4925_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0301-472X(03)00023-7","volume":"31","author":"S Greenstein","year":"2003","unstructured":"Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol. 2003;31:271\u201382.","journal-title":"Exp Hematol"},{"key":"4925_CR24","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","volume":"113","author":"G Bianchi","year":"2009","unstructured":"Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009;113:3040\u20139.","journal-title":"Blood."},{"key":"4925_CR25","doi-asserted-by":"publisher","first-page":"e56132","DOI":"10.1371\/journal.pone.0056132","volume":"8","author":"TB Shabaneh","year":"2013","unstructured":"Shabaneh TB, Downey SL, Goddard AL, Screen M, Lucas MM, Eastman A, et al. Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS ONE. 2013;8:e56132.","journal-title":"PLoS ONE"},{"key":"4925_CR26","first-page":"1441","volume":"11","author":"Z Canturk","year":"2016","unstructured":"Canturk Z, Dikmen M, Artagan O, Ozarda MG, Ozturk N. Cytotoxic effects of resveratrol, rutin and rosmarinic acid on ARH-77 human (multiple myeloma) cell line. Nat Prod Commun. 2016;11:1441\u20134.","journal-title":"Nat Prod Commun"},{"key":"4925_CR27","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/1097-0142(19841101)54:9<1883::AID-CNCR2820540919>3.0.CO;2-Q","volume":"54","author":"B Drewinko","year":"1984","unstructured":"Drewinko B, Mars W, Minowada J, Burk KH, Trujillo JM. ARH-77, an established human IgG-producing myeloma cell line. I. Morphology, B-cell phenotypic marker profile, and expression of Epstein-Barr virus. Cancer. 1984;54:1883\u201392.","journal-title":"Cancer."},{"key":"4925_CR28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0145-2126(99)00195-2","volume":"24","author":"HG Drexler","year":"2000","unstructured":"Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk Res. 2000;24:681\u2013703.","journal-title":"Leuk Res"},{"key":"4925_CR29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1182\/bloodadvances.2020003820","volume":"6","author":"T Chen","year":"2022","unstructured":"Chen T, Ho M, Briere J, Moscvin M, Czarnecki PG, Anderson KC, et al. Multiple myeloma cells depend on the DDI2\/NRF1-mediated proteasome stress response for survival. Blood Adv. 2022;6:429\u201340.","journal-title":"Blood Adv"},{"key":"4925_CR30","first-page":"274","volume":"7","author":"S Shimizu","year":"1993","unstructured":"Shimizu S, Takiguchi T, Fukutoku M, Yoshioka R, Hirose Y, Fukuhara S, et al. Establishment of a CD4-positive plasmacytoma cell line (AMO1). Leukemia. 1993;7:274\u201380.","journal-title":"Leukemia."},{"key":"4925_CR31","doi-asserted-by":"publisher","first-page":"109775","DOI":"10.1016\/j.cellsig.2020.109775","volume":"75","author":"Y Gu","year":"2020","unstructured":"Gu Y, Wang X, Wang Y, Wang Y, Li J, Yu FX. Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors. Cell Signal. 2020;75:109775.","journal-title":"Cell Signal"},{"key":"4925_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep30443","volume":"6","author":"M Siva","year":"2016","unstructured":"Siva M, Svoboda M, Veverka V, Trempe JF, Hofmann K, Kozisek M, et al. Human DNA-damage-inducible 2 protein is structurally and functionally distinct from its yeast ortholog. Sci Rep. 2016;6:30443.","journal-title":"Sci Rep"},{"key":"4925_CR33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.0022-202X.2005.23816.x","volume":"125","author":"D Bernard","year":"2005","unstructured":"Bernard D, Mehul B, Thomas-Collignon A, Delattre C, Donovan M, Schmidt R. Identification and characterization of a novel retroviral-like aspartic protease specifically expressed in human epidermis. J Invest Dermatol. 2005;125:278\u201387.","journal-title":"J Invest Dermatol"},{"key":"4925_CR34","doi-asserted-by":"publisher","first-page":"27512","DOI":"10.1074\/jbc.M603559200","volume":"281","author":"T Matsui","year":"2006","unstructured":"Matsui T, Kinoshita-Ida Y, Hayashi-Kisumi F, Hata M, Matsubara K, Chiba M, et al. Mouse homologue of skin-specific retroviral-like aspartic protease involved in wrinkle formation. J Biol Chem. 2006;281:27512\u201325.","journal-title":"J Biol Chem"},{"key":"4925_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.87","volume":"3","author":"S Kawabata","year":"2012","unstructured":"Kawabata S, Gills JJ, Mercado-Matos JR, Lopiccolo J, Wilson W 3rd, Hollander MC, et al. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death Dis. 2012;3:e353.","journal-title":"Cell Death Dis"},{"key":"4925_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.2","volume":"3","author":"M Kraus","year":"2013","unstructured":"Kraus M, Bader J, Overkleeft H, Driessen C. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J. 2013;3:e103.","journal-title":"Blood Cancer J"},{"key":"4925_CR37","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-07-0161","volume":"13","author":"JJ Gills","year":"2007","unstructured":"Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007;13:5183\u201394.","journal-title":"Clin Cancer Res"},{"key":"4925_CR38","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.15252\/embr.201642194","volume":"17","author":"A De Gassart","year":"2016","unstructured":"De Gassart A, Demaria O, Panes R, Zaffalon L, Ryazanov AG, Gilliet M, et al. Pharmacological eEF2K activation promotes cell death and inhibits cancer progression. EMBO Rep. 2016;17:1471\u201384.","journal-title":"EMBO Rep"},{"key":"4925_CR39","doi-asserted-by":"publisher","first-page":"1065.","DOI":"10.3390\/cancers12051065","volume":"12","author":"D Fassmannova","year":"2020","unstructured":"Fassmannova D, Sedlak F, Sedlacek J, Spicka I, Grantz Saskova K. Nelfinavir inhibits the TCF11\/Nrf1-mediated proteasome recovery pathway in multiple myeloma. Cancers (Basel). 2020;12:1065.","journal-title":"Cancers (Basel)"},{"key":"4925_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/srep09698","volume":"5","author":"M Guan","year":"2015","unstructured":"Guan M, Su L, Yuan YC, Li H, Chow WA. Nelfinavir and nelfinavir analogs block site-2 protease cleavage to inhibit castration-resistant prostate cancer. Sci Rep. 2015;5:9698.","journal-title":"Sci Rep"},{"key":"4925_CR41","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41416-020-01191-y","volume":"124","author":"M Ge","year":"2021","unstructured":"Ge M, Qiao Z, Kong Y, Liang H, Sun Y, Lu H, et al. Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance. Br J Cancer. 2021;124:770\u20136.","journal-title":"Br J Cancer"},{"key":"4925_CR42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","volume":"20","author":"MG Netea","year":"2020","unstructured":"Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20:375\u201388.","journal-title":"Nat Rev Immunol"},{"key":"4925_CR43","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1073\/pnas.1915534117","volume":"117","author":"GA Collins","year":"2020","unstructured":"Collins GA, Goldberg AL. Proteins containing ubiquitin-like (Ubl) domains not only bind to 26S proteasomes but also induce their activation. Proc Natl Acad Sci USA. 2020;117:4664\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4925_CR44","doi-asserted-by":"publisher","first-page":"7776","DOI":"10.1073\/pnas.1902298117","volume":"117","author":"MCJ Yip","year":"2020","unstructured":"Yip MCJ, Bodnar NO, Rapoport TA. Ddi1 is a ubiquitin-dependent protease. Proc Natl Acad Sci USA. 2020;117:7776\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4925_CR45","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1182\/blood-2018-05-851170","volume":"132","author":"C Driessen","year":"2018","unstructured":"Driessen C, Muller R, Novak U, Cantoni N, Betticher D, Mach N, et al. Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma. Blood. 2018;132:2097\u2013100.","journal-title":"Blood."},{"key":"4925_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.14740\/wjon1241","volume":"11","author":"A Erath","year":"2020","unstructured":"Erath A, Patel DA, Hosack EA, Patanella JE, Ibach DM, Kassim AA. Overcoming proteasome inhibitor-refractory multiple myeloma with elotuzumab, bortezomib, nelfinavir, and dexamethasone. World J Oncol. 2020;11:33\u20136.","journal-title":"World J Oncol"},{"key":"4925_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0228-2","volume":"9","author":"F Hitz","year":"2019","unstructured":"Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, et al. Nelfinavir and lenalidomide\/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I\/II Trial (SAKK 39\/10). Blood Cancer J. 2019;9:70.","journal-title":"Blood Cancer J"},{"key":"4925_CR48","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1158\/0008-5472.CAN-20-3323","volume":"81","author":"L Besse","year":"2021","unstructured":"Besse L, Besse A, Stolze SC, Sobh A, Zaal EA, van der Ham AJ, et al. Treatment with HIV-protease inhibitor nelfinavir identifies membrane lipid composition and fluidity as a therapeutic target in advanced multiple myeloma. Cancer Res. 2021;81:4581\u201393.","journal-title":"Cancer Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04925-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:53:23Z","timestamp":1669301603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04925-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["4925"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-04925-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"14 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"475"}}